En Es
Categories

Industry News

Global COVID-19 Saliva Screening Test Market to Reach USD 3,406.2 Billion by 2023

By Labmedica International staff writers
09 Jun 2021

IllustrationThe global COVID-19 saliva screening test potential market size is expected to expand at a CAGR of 4.8% from USD 2955.9 billion in 2021 to USD 3,406.2 billion by 2023, driven by a rise in the demand for rapid, efficient, saliva-based screening tests.

These are the latest findings of Grand View Research, Inc. (San Francisco, CA, USA), a market research and consulting company.

Saliva-based screening for SARS-CoV-2 is gaining traction in the current scenario, as it is easy to use, patient-friendly, and has a shorter test-to-result timeline. Saliva-based tests play a vital role in screening asymptomatic individuals, thereby aiding in market revenue generation in the near future. This is primarily due to the various advantages offered by saliva-based tests, increasing product approvals by regulatory bodies, and a paradigm shift toward point-of-care testing.

The fluorescence-labeled antigen/antibodies test is one of the recent saliva-based COVID-19 screening tests in the market that is based on the principles of fluorescence detection, biochemistry, robotics automation, and cloud computing. The fluorescence-labeled antigen/antibodies test is designed to accelerate rapid point-of-access testing of individuals.

Owing to the pandemic, the economy across various sectors is severely impacted. However, with the reopening of various sectors and locations such as shopping malls and amusement parks, there is a growing need for screening individuals to curb viral transmission. As the number of people visiting public places is increasing and reaching pre-pandemic statistics in a few countries, there is a growing demand for rapid, point-of-care COVID-19 tests to mitigate viral transmission from asymptomatic people. Thus, there is high growth potential for the market with the increase in usage of the medical test at various locations to screen individuals. This has enhanced the R&D for the development of simple yet effective saliva-based tests and is expected to create lucrative opportunities for several developers. Regulatory bodies such as the US FDA and European Medicine Agency (EMA) have supported these products by providing EUA and product approvals.

Globally, North America dominated the global market owing to the high penetration and adoption of saliva-based screening tests in the region. The US is the major contributor to revenue generation due to the emergence of new small and mid-sized companies engaged in the development of such tests.

Related Links:
Grand View Research, Inc.



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

15 Jun 2021
Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device
Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA).
Read More
15 Jun 2021
Global PET-CT Scanner Device Market to Reach USD 3.34 Billion by 2028
The global PET-CT scanner device market size is expected to register a CAGR of 6.6% from 2021 to 2028 to reach USD 3.34 billion by 2028, driven primarily by the increasing need to overcome the shortfalls of CT and PET in oncology imaging.
Read More
11 Jun 2021
Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028
The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population, technological improvements in point of care testing devices, and development of laboratory automation.
Read More
20 May 2021
Global Lateral Flow Assays Market to Reach USD 13.85 Billion by 2027 Due to Benefits of Rapid Tests and Growing Demand for POC Testing
The global lateral flow assays market is expected to grow at a CAGR of 8.8% from 2020 to 2027 to reach USD 13.85 billion by 2027, driven mainly by the benefits of LFA-based rapid tests over laboratory testing and growing demand for point-of-care testing.
Read More
18 May 2021
PerkinElmer to Acquire UK In-Vitro Diagnostics Company Immunodiagnostic Systems
PerkinElmer, Inc. (Waltham, MA; USA) and Immunodiagnostic Systems Holdings PLC (IDS; Boldon, Tyne and Wear, UK) have reached an agreement whereby PerkinElmer will acquire IDS for approximately USD 155 million.
Read More
14 May 2021
Siemens Launches its Fastest, Single-Source CT Scanner, Somatom X.ceed
Siemens Healthineers (Erlangen, Germany) has launched Somatom X.ceed, a new high-resolution, high-speed CT (computed tomography) scanner engineered specifically for the most challenging clinical areas where time and precision are of essence.
Read More
14 May 2021
Carestream Unveils Groundbreaking AI-Based Technology that Advances X-Ray Image Quality
Carestream Health (Rochester, N.Y., USA) has released Smart Noise Cancellation (SNC), a groundbreaking artificial intelligence (AI)-based technology that greatly improves image quality - producing images that are significantly clearer than with standard processing.
Read More
12 May 2021
Artificial Intelligence (AI) Program Accurately Predicts Lung Cancer Risk from CT Images
An artificial intelligence (AI) program accurately predicts the risk that lung nodules detected on screening CT will become cancerous, according to a study published in the journal Radiology.
Read More
05 May 2021
Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories
Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions